Literature DB >> 23471343

[Secondary prophylaxis of stroke from a neurological perspective].

G Seidel1.   

Abstract

Patients who have suffered ischemic stroke or transient ischemic attack (TIA) are at high risk of recurrent stroke, myocardial infarction or vascular death. Early pathophysiological based diagnostics and resulting secondary prevention are critical for reduction of stroke risk. Optimization of lifestyle factors, treatment of hypertension, cholesterol reduction with statins and use of antiplatelet agents in non-cardiogenic or anticoagulation in cardiogenic ischemia as well as internal carotid revascularization, in cases of more than 50% diameter stenosis of the internal carotid artery, are proven strategies for reduction of ischemic stroke risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471343     DOI: 10.1007/s00059-013-3774-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  69 in total

1.  Blood pressure and stroke: an overview of published reviews.

Authors:  Carlene M M Lawes; Derrick A Bennett; Valery L Feigin; Anthony Rodgers
Journal:  Stroke       Date:  2004-04       Impact factor: 7.914

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

4.  Semi-intensive stroke unit versus conventional care in acute ischemic stroke or TIA--a prospective study in Germany.

Authors:  Andreas Walter; Guenter Seidel; Andreas Thie; Heiner Raspe
Journal:  J Neurol Sci       Date:  2009-09-06       Impact factor: 3.181

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 6.  Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis.

Authors:  Matthew F Giles; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2007-11-13       Impact factor: 44.182

7.  Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome.

Authors:  José Castillo; Rogelio Leira; María M García; Joaquín Serena; Miguel Blanco; Antoni Dávalos
Journal:  Stroke       Date:  2004-01-15       Impact factor: 7.914

8.  Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.

Authors:  P H A Halkes; L J Gray; P M W Bath; H-C Diener; B Guiraud-Chaumeil; F M Yatsu; A Algra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-06-05       Impact factor: 10.154

9.  Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.

Authors:  Reinhard Dengler; Hans-Christoph Diener; Andreas Schwartz; Martin Grond; Helmut Schumacher; Thomas Machnig; Christoph Cyrill Eschenfelder; Joachim Leonard; Karin Weissenborn; Andreas Kastrup; Roman Haberl
Journal:  Lancet Neurol       Date:  2010-01-07       Impact factor: 44.182

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.